TRON Founder Justin Sun Attends the Inaugural NFTBERLIN with His Twelve Digital Zodiac Heads Collection
On May 24, NFTBERLIN tweeted that Justin Sun, the founder of TRON, confirmed attendance at the first NFTBERLIN event virtually and participation in a panel discussion on the future trends of NFT. He will exhibit many of his valuable collections, including the Twelve Digital Zodiac Heads, which are to be presented to the public for the first time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220522005048/en/
TRON Founder Justin Sun Attends the Inaugural NFTBERLIN with His Twelve Digital Zodiac Heads Collection (Graphic: Business Wire)
NFTBERLIN is a community-led unconference and exhibition focusing on the innovative development of NFT. The inaugural event will be held in Berlin, Germany, from May 25 to May 27, where creators, collectors, artists, and other art enthusiasts worldwide will meet to discuss the trends and future of the NFTverse.
The NFTBERLIN event consists of three sessions: an NFT art exhibition, symposium, and Hackathon. Themed on the NFT, the symposium will invite well-known artists, collectors, and platforms in the NFT space both home and abroad to interpret the history, present, and future of NFTs through speeches, dialogues, round table discussions, etc. The NFT art exhibition will be held in Alte Münze, Berlin, from May 25 to 26 and will feature works by renowned and emerging artists from around the world, including the Twelve Digital Zodiac Heads previously bought by Justin Sun at ¥9,832,500. This collection was created based on the traditional Chinese Zodiac signs and minted as NFTs with blockchain technology. It is the only set in existence.
An art collector and an early NFT practitioner, Justin Sun was also invited to this NFTBERLIN event. Sun has acquired many works by world-renowned artists in the past two years, including the Twelve Digital Zodiac Heads, Beeple's Ocean Front, and Fewocious' My Mama's Dream, which will be featured in the NFTBERLIN art exhibition. He has also clinched Picasso's Femme Nue Couchée au Collier (Marie-Thérèse), Andy Warhol's Three Self Portraits, and Alberto Giacometti's The Nose, among other masterpieces, with a combined worth of over ¥1 billion.
NFTBERLIN is Europe's largest offline NFT event initiated by DAOs to date. Aiming to bring together outstanding independent crypto artists to prove that "the whole is greater than the sum of its parts" and promote the development of crypto art further, the event has attracted many institutions and big names from the industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220522005048/en/
Contact information
Jessica ZHANG
jessica.zhang01@tron.network
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Adds González-Paullada Domínguez in Monterrey, Mexico7.1.2026 16:30:00 EET | Press release
Andersen Global broadens its Latin American platform through a Collaboration Agreement with Monterrey-based law firm González-Paullada Domínguez (GPD), further strengthening the organization’s coverage in Mexico. Founded in 2021, GPD offers comprehensive services across transactional and litigation matters. The firm advises clients across sectors—including manufacturing, real estate, insurance, information technology, mining, and banking—on corporate law, mergers and acquisitions, real estate transactions, foreign investment, commercial contracts, regulatory compliance, and ongoing legal audits. GPD also represents clients in complex civil and commercial litigation, arbitration, and insolvency proceedings. “Monterrey is a major economic hub where local credibility and deep relationships are essential, particularly for foreign investors seeking to enter the market,” said Alfonso González-Paullada Guerrero, founder and managing partner of GPD. “By collaborating with Andersen Global, we s
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 15:15:00 EET | Press release
1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new intelligent data program called 1NCE Insights. The program is part of the company’s goal of fusing AI + IoT intelligence to drive game-changing results in supply chains, smart cities, utilities and beyond. Customer-collected data is theirs and theirs alone. But with Insights, 1NCE opens access to its anonymized, networkwide data. Customers can benchmark their IoT projects a
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 15:00:00 EET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom